Three Dosing Schedules of Oral Rigosertib in MDS Patients

Myelodysplastic Syndrome Clinical Trial

Official title:

A Randomized Phase I Study to Assess the Pharmacokinetics, Tolerability, Efficacy and Pharmacodynamics of Three Dosing Schedules of Oral Rigosertib in Transfusion-dependent, Low, Intermediate 1, or Intermediate-2 Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02075034
• Other study ID #: Onconova 09-10
• Status: Withdrawn
• Phase: Phase 1
• Start date: May 2014
• Est. completion date: November 2019

Study information

• Verified date: July 2018
• Source: Onconova Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will compare the dosing regimen of oral rigosertib, which has been used in other studies of lower risk Myelodysplastic Syndrome (MDS), with 2 new dosing regimens to determine if one of the new regimens gives improved results as measured by disease status, side effects, and analyses of blood and urine samples.

Description:

This will be a Phase I, randomized, 3-treatment arm, single-center study in transfusion-dependent Myelodysplastic Syndrome (MDS) patients classified as Low- or Intermediate-1 (Int-1) or Intermediate-2 (Int-2) risk by the International Prognostic Scoring System (IPSS). Initially, 18 patients (6 per treatment arm) will be randomized in a 1:1:1 ratio to 1 of 3 oral rigosertib dosing regimens, each of which is a cycle consisting of 14 consecutive days of dosing followed by 7 days off drug.

Treatment with erythropoiesis-stimulating agent (ESA) is prohibited for the first 15 weeks (5 cycles). After 15 weeks of dosing (5 cycles), ESA treatment will be initiated if the patient still needs red blood cell (RBC) transfusions and if the pre-transfusion hemoglobin (Hgb) value is ≤ 9 g/dL, unless the clinical judgment of the Investigator determines ESA administration to a patient with a Hgb level > 9 g/dL is warranted.

All study participants will be allowed, as medically justified, access to RBC and platelet (PLT) transfusions, and to filgrastim. Rigosertib dosing adjustment policies are described.

After all 18 patients have completed 3 cycles, a risk/benefit analysis will be completed assessing the distribution of adverse events (AEs) and serious adverse events (SAEs) and the number of transfusions among the 3 treatment arms. This analysis will select 1 of the 3 dosing regimens as having the best risk/benefit profile and an additional 12 to 18 patients will be enrolled at this dosing regimen. Eligibility criteria may be modified by protocol amendments to enroll patients with different characteristics. All patients will be treated for 48 weeks or until 2006 International Working Group (IWG) progression criteria are met, unacceptable toxicity is observed, intercurrent illness or a change in the patient's condition prevents further administration of study drug treatment, or until death from any cause occurs, whichever comes first. Patients who have continued hematologic response at 48 weeks may continue to be treated in the study beyond 48 weeks until 2006 IWG progression criteria are met or until death from any cause, whichever comes first.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2019
• Est. primary completion date: August 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of MDS according to World Health Organization (WHO) criteria or French-American-British (FAB) classification that must be confirmed by bone marrow (BM) aspirate and/or biopsy within 6 weeks prior to Screening.

• MDS classified as Low-risk or Int-1 risk or Int-2 risk according to International Prognostic Scoring System (IPSS) classification; in addition, patients should never have been classified as High-risk since their MDS was diagnosed.

• Transfusion dependency defined by transfusion of at least 4 units of RBC (red blood cells) within 8 weeks before Screening; pre-transfusion Hgb (hemoglobin) values must be = 9 g/dL to be taken into account.

• Refractory to 8- to 12-week course of ESA (erythropoiesis stimulating agent) administered within the past 2 years before enrollment, or erythropoietin (EPO) level ? 500 mU/mL and off ESA for at least 8 weeks before Screening.

• Off all other treatments for MDS for at least 2 weeks prior to Screening.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

• Willing to adhere to the prohibitions and restrictions specified in the protocol.

• The patient must signed an informed consent form (ICF).

Exclusion Criteria:

• Ongoing clinically significant anemia due to factors such as iron, vitamin B12, or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal bleeding.

• Serum ferritin < 50 ng/mL.

• Hypoplastic MDS (cellularity < 10%).

• Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.

• Uncontrolled intercurrent illness.

• Active infection not adequately responding to appropriate therapy.

• Total bilirubin = 2.0 mg/dL not related to hemolysis or Gilbert's disease.

• Alanine transaminase (ALT) or aspartate transaminase (AST) = 2.5 x the upper limit of normal (ULN).

• Serum creatinine = 2.0 mg/dL.

• Ascites requiring active medical management including paracentesis.

• Hyponatremia (defined as serum sodium value of < 130 mEq/L).

• Female patients of child-bearing potential or male patients with partners of child-bearing potential who are unwilling to follow strict contraception requirements before entry and throughout the study, up to and including the 30-day non-treatment follow-up period.

• Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening or who are lactating.

• Major surgery without full recovery or major surgery within 3 weeks of Screening.

• Uncontrolled hypertension (defined as a systolic pressure = 160 mmHg and/or a diastolic pressure = 110 mmHg).

• New onset seizures (within 3 months prior to the first dose of rigosertib) or poorly controlled seizures.

• Any other concurrent chemotherapy, radiotherapy, or immunotherapy.

• Chronic use (? 2 weeks) of corticosteroids (? 10 mg/24 hour equivalent prednisone) within 4 weeks of Baseline/Cycle 1 Day 1 visit.

• Investigational therapy within 4 weeks of Screening.

• Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.

Related Conditions & MeSH terms

• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• rigosertib
Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.

Locations

Country	Name	City	State
United States	Columbia University Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Onconova Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Micrograms of rigosertib per milliliter of plasma	Concentration of rigosertib in plasma will be determined by validated high performance liquid chromatography (HPLC) method.	0, 0.5, 1, 1.5, 2, 4, 6, and 8 hour on Day 1 of Cycle 1 and on Day 1 of Cycle 2.
Primary	Micrograms of rigosertib per milliliter of urine	Concentration of rigosertib in urine will be determined by a validated high performance liquid chromatography (HPLC) method.	Cycle 1 Day 1 and Cycle 2 Day 1 in dosing Regimens 1 and 2 and Cycle 1 Day 1 and Cycle 2 Day 21 in dose Regimen 3
Primary	Number of patients with adverse events	Adverse events will be summarized by worst grade according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.; All AE presentations will summarize treatment-emergent adverse events (TEAEs), defined as AEs with onset on or after first dose, or onset prior to first dose but with worsening severity after first dose.	Until 30 days after last dose of study drug (up to 52 weeks)
Secondary	Proportion of patients with hematologic improvement (HI)	HI is defined according to IWG criteria (Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108:419-25.) and include Erythroid response, Neutrophil response and Platelet response.	24 weeks
Secondary	Concentration of biomarkers in urine	Biomarkers will be measured by immunoassay.	Up to Cycle 2 Day 15 (up to day 36)